Madrigal pharmaceuticals announces nda acceptance and priority review of the new drug application for resmetirom for the treatment of nash with liver fibrosis

Conshohocken, pa., sept. 13, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that the u.s. food and drug administration (fda) has accepted for review its new drug application (nda) for resmetirom for the treatment of adult patients with nash with liver fibrosis. the fda has granted priority review and assigned a prescription drug user fee act date for resmetirom of march 14, 2024, the target date by which the fda intends to complete its review and take action on the nda. the agency noted that it is not currently planning to hold an advisory committee meeting to discuss the application.
MDGL Ratings Summary
MDGL Quant Ranking